(EVLV) Evolv Technologies Holdings - Overview
Stock: AI Weapons Scanner, Analytics Software
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 71.7% |
| Relative Tail Risk | -20.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.68 |
| Alpha | 11.37 |
| Character TTM | |
|---|---|
| Beta | 1.213 |
| Beta Downside | 0.903 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.92% |
| CAGR/Max DD | 0.29 |
Description: EVLV Evolv Technologies Holdings January 20, 2026
Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) develops AI-driven weapons-detection solutions for security screening across a range of venues-including schools, hospitals, sports arenas, and places of worship. Its flagship offering, the Evolv Express, scans individuals for firearms, IEDs and tactical knives, while the Evolv eXpedite system extends detection to bags. Complementary analytics are delivered through Evolv Insights, which provides real-time data on visitor flow, alarm rates and system performance.
Since its 2013 founding in Waltham, Massachusetts, Evolv has reported a compound annual revenue growth of roughly 45 % over the past three years (2021-2023), driven by expanding contracts with large-scale public venues and a growing backlog of multi-year agreements. The company’s gross margin has stabilized near 70 %, reflecting the high-value, software-centric nature of its AI platform.
The security-screening market is being accelerated by two macro trends: (1) heightened public-safety spending in the United States-federal and state budgets for school and venue security have risen at an average 8 % YoY since 2020; and (2) rapid adoption of AI-based detection technologies, which are projected to capture >30 % of new security-screening deployments by 2027, according to a recent IDC forecast.
For a deeper dive into EVLV’s valuation metrics, the ValueRay platform offers a granular breakdown of its financials and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -59.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 18.95 > 1.0 |
| NWC/Revenue: 23.66% < 20% (prev 46.36%; Δ -22.70% < -1%) |
| CFO/TA 0.02 > 3% & CFO 6.30m > Net Income -59.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (172.8m) vs 12m ago 9.16% < -2% |
| Gross Margin: 53.78% > 18% (prev 0.54%; Δ 5324 % > 0.5%) |
| Asset Turnover: 46.85% > 50% (prev 34.80%; Δ 12.05% > 0%) |
| Interest Coverage Ratio: -60.57 > 6 (EBITDA TTM -25.4m / Interest Expense TTM 714.0k) |
Altman Z'' -6.64
| A: 0.11 (Total Current Assets 151.6m - Total Current Liabilities 119.3m) / Total Assets 304.3m |
| B: -1.31 (Retained Earnings -398.7m / Total Assets 304.3m) |
| C: -0.15 (EBIT TTM -43.2m / Avg Total Assets 291.4m) |
| D: -1.97 (Book Value of Equity -398.8m / Total Liabilities 202.1m) |
| Altman-Z'' Score: -6.64 = D |
Beneish M -2.73
| DSRI: 1.02 (Receivables 50.1m/34.9m, Revenue 136.5m/96.9m) |
| GMI: 1.01 (GM 53.78% / 54.38%) |
| AQI: 1.33 (AQ_t 0.04 / AQ_t-1 0.03) |
| SGI: 1.41 (Revenue 136.5m / 96.9m) |
| TATA: -0.22 (NI -59.7m - CFO 6.30m) / TA 304.3m) |
| Beneish M-Score: -2.73 (Cap -4..+1) = A |
What is the price of EVLV shares?
Over the past week, the price has changed by -11.31%, over one month by -24.79%, over three months by -20.09% and over the past year by +31.97%.
Is EVLV a buy, sell or hold?
- StrongBuy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EVLV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.9 | 80% |
| Analysts Target Price | 9.9 | 80% |
| ValueRay Target Price | 5.7 | 3.6% |
EVLV Fundamental Data Overview February 02, 2026
P/S = 7.9185
P/B = 10.8628
Revenue TTM = 136.5m USD
EBIT TTM = -43.2m USD
EBITDA TTM = -25.4m USD
Long Term Debt = 28.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.77m USD (from shortTermDebt, last quarter)
Debt = 42.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.07b USD (1.08b + Debt 42.4m - CCE 56.2m)
Interest Coverage Ratio = -60.57 (Ebit TTM -43.2m / Interest Expense TTM 714.0k)
EV/FCF = -31.37x (Enterprise Value 1.07b / FCF TTM -34.0m)
FCF Yield = -3.19% (FCF TTM -34.0m / Enterprise Value 1.07b)
FCF Margin = -24.92% (FCF TTM -34.0m / Revenue TTM 136.5m)
Net Margin = -43.77% (Net Income TTM -59.7m / Revenue TTM 136.5m)
Gross Margin = 53.78% ((Revenue TTM 136.5m - Cost of Revenue TTM 63.1m) / Revenue TTM)
Gross Margin QoQ = 49.72% (prev 49.83%)
Tobins Q-Ratio = 3.51 (Enterprise Value 1.07b / Total Assets 304.3m)
Interest Expense / Debt = 1.68% (Interest Expense 713.0k / Debt 42.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -34.2m (EBIT -43.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.27 (Total Current Assets 151.6m / Total Current Liabilities 119.3m)
Debt / Equity = 0.41 (Debt 42.4m / totalStockholderEquity, last quarter 102.2m)
Debt / EBITDA = -0.43 (negative EBITDA) (Net Debt 10.9m / EBITDA -25.4m)
Debt / FCF = -0.32 (negative FCF - burning cash) (Net Debt 10.9m / FCF TTM -34.0m)
Total Stockholder Equity = 108.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.50% (Net Income -59.7m / Total Assets 304.3m)
RoE = -55.11% (Net Income TTM -59.7m / Total Stockholder Equity 108.4m)
RoCE = -31.58% (EBIT -43.2m / Capital Employed (Equity 108.4m + L.T.Debt 28.5m))
RoIC = -29.57% (negative operating profit) (NOPAT -34.2m / Invested Capital 115.5m)
WACC = 10.05% (E(1.08b)/V(1.12b) * Re(10.39%) + D(42.4m)/V(1.12b) * Rd(1.68%) * (1-Tc(0.21)))
Discount Rate = 10.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.94%
Fair Price DCF = unknown (Cash Flow -34.0m)
EPS Correlation: 84.26 | EPS CAGR: 105.0% | SUE: 0.97 | # QB: 1
Revenue Correlation: 90.32 | Revenue CAGR: 63.08% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.02 | Chg30d=+0.005 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.05 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+46.2% | Growth Revenue=+14.7%